Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Valeant Prepares For Phase III Retigabine Studies In Epilepsy

July 27, 2005

By Jennifer Boggs

Valeant Prepares For Phase III Retigabine Studies In Epilepsy

July 27, 2005

By Jennifer Boggs

Novacea Gains Rights To Oral Vinorelbine From Pierre Fabre

July 26, 2005

By Jennifer Boggs

Novacea Gains Rights To Oral Vinorelbine From Pierre Fabre

July 26, 2005

By Jennifer Boggs

Advancis' Amoxicillin Pulsys Fails In Second Phase III Trial

July 25, 2005

By Jennifer Boggs

Advancis' Amoxicillin Pulsys Fails In Second Phase III Trial

July 25, 2005

By Jennifer Boggs

Dendreon Rises On Provenge Survival Data; Considers BLA

July 22, 2005

By Jennifer Boggs

Dendreon Rises On Provenge Survival Data; Considers BLA

July 22, 2005

By Jennifer Boggs

EPIX's Phase II Trial Delayed For Blood Clot Imaging Agent

July 21, 2005

By Jennifer Boggs

EPIX's Phase II Trial Delayed For Blood Clot Imaging Agent

July 21, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...